Compass Therapeutics Inc. (CMPX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) has a cash flow conversion efficiency ratio of -0.081x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.42 Million) by net assets ($166.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Compass Therapeutics Inc. for the company's overall valuation and market capitalisation.
Compass Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Compass Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Compass Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Therapeutics Inc. ranked by their cash flow conversion efficiency. See how well can Compass Therapeutics Inc. service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SMS Electric Co Ltd Zhengzhou
SHE:002857
|
-0.037x |
|
Sk Securities
KO:001510
|
-0.132x |
|
F-SECURE OYJ
HE:FSECURE
|
0.094x |
|
Nanjing OLO Home Furnishing
SHG:603326
|
0.055x |
|
FVCBankcorp Inc
NASDAQ:FVCB
|
0.062x |
|
Hospital Mater Dei S.A
SA:MATD3
|
0.000x |
|
Wildcat Resources Ltd
AU:WC8
|
-0.002x |
|
ZCCM Investments Holdings Plc
PA:MLZAM
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Compass Therapeutics Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Compass Therapeutics Inc. from 2018 to 2025. View Compass Therapeutics Inc. (CMPX) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.79 Million | $-49.14 Million | -0.250x | +30.28% |
| 2024-12-31 | $125.23 Million | $-44.85 Million | -0.358x | -30.98% |
| 2023-12-31 | $148.54 Million | $-40.62 Million | -0.273x | -45.55% |
| 2022-12-31 | $181.64 Million | $-34.12 Million | -0.188x | -33.82% |
| 2021-12-31 | $140.08 Million | $-19.67 Million | -0.140x | +79.08% |
| 2020-12-31 | $39.95 Million | $-26.80 Million | -0.671x | -350.72% |
| 2019-12-31 | $-118.60 Million | $-31.74 Million | 0.268x | -32.64% |
| 2018-12-31 | $-84.77 Million | $-33.68 Million | 0.397x | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tum… Read more